ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 516 • 2018 ACR/ARHP Annual Meeting

    Microalbuminuria in Rheumatoid Arthritis: Investigating the Association with Diffuse Functional and Morphological Alterations of the Retinal Microvasculature, the Dermal Capillary Network and the Coronary Microcirculation

    Panagiota Anyfanti1, Areti Triantafyllou1, Eugenia Gkaliagkousi1, Xenophon Zabulis2, Sophia Chatzimichailidou3, Vasiliki Galanopoulou4, Stella Douma1 and Spyros Aslanidis3, 13rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, 2Institute of Computer Science, Foundation for Research and Technology-Hellas (FORTH), Heraklion, Greece, Heraklion, Greece, 3Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, 4Rheumatology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece

    Background/Purpose: Increased urinary albumin excretion (UAE) is an early marker of renal microvascular damage that correlates with cardiovascular risk and corresponds to a state of…
  • Abstract Number: 517 • 2018 ACR/ARHP Annual Meeting

    Effects of Statin-Treatment on Coronary Plaques in Patients with Inflammatory Joint Diseases

    Silvia Rollefstad1, Mona Svanteson2, Nils Einar Kløw2,3, Jonny Hisdal4, Eirik Ikdahl5, Joseph Sexton6, Ylva Haig2 and Anne Grete Semb1, 1Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Division of Radiology and Nuclear Medicine, Oslo University Hospital, Ullevål, Oslo, Norway, 3Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, 4Department of Vascular investigations, Oslo University Hospital, Aker, Oslo, Norway, 5Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 6Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Effects of Statin-treatment on Coronary Plaques in Patients with Inflammatory Joint DiseasesBackground/Purpose: Statins have an established preventive effect on coronary artery disease in the general…
  • Abstract Number: 518 • 2018 ACR/ARHP Annual Meeting

    Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis

    Sulé Gunter1, Lebogang Mokotedi2, Monica Gomez2, Linda Tsang2, Aletta Millen3 and Patrick Dessein2, 1Depeartment of Health Sciences, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa, 2Department of Health Sciences, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa, 3Department of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: The rheumatoid arthritis (RA) population demonstrate a significantly increased incidence of cardiac events. Cardiac dysfunction in RA may occur as a result of impaired…
  • Abstract Number: 519 • 2018 ACR/ARHP Annual Meeting

    Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry

    Huifeng Yun1, Lang Chen1, Jason Roy2, Jeffrey D. Greenberg3 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Pennsylvania, Philadelphia, PA, 3Hopital Hautepierre, Strasbourg, France

    Background/Purpose: Higher disease activity might be associated with a higher risk of developing infections among patients with rheumatoid arthritis (RA). Since no randomized trial has…
  • Abstract Number: 520 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with the Developement of Severe Respiratory Infections in Patients with Rheumatoid Arthritis Included in a Vaccination Program

    Lucia C. Domínguez-Casas1, Paz Rodríguez-Cundín2, Vanesa Calvo-Río3, Nuria Vegas-Revenga3, Virginia Portilla4, F. Antolin2, M. Rebollo-Rodrigo2, Alfonso Corrales1, Diana Prieto Peña3, Monica Calderón Goercke3, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain, 3Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Rheumatoid arthritis(RA) patients are at increased risk of infections particularly respiratory infections. These may be augmented due to RA itself and to immunosuppressive durgs,…
  • Abstract Number: 521 • 2018 ACR/ARHP Annual Meeting

    The Lung in an English Cohort of Rheumatoid Arthritis Patients – an Overview of Different Types of Involvement and Treatment

    Ana Catarina Duarte1, Maria José Leandro2 and Joanna Porter3, 1Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 2Center for Rheumatology, University College London, London, United Kingdom, London, United Kingdom, 3Department of Respiratory Medicine, University College London, London, United Kingdom, London, United Kingdom

    Background/Purpose: Lung disease is described in 5–20% of pts (pts) with RA and affects parenchyma, pleura, airways and vasculature; drug-induced pulmonary disease also occurs. It…
  • Abstract Number: 522 • 2018 ACR/ARHP Annual Meeting

    Analysis of Sequential Development of Pulmonary Lesions in Patients with Rheumatoid Arthritis

    Ayae Tanaka1, Kazuhiro Kurasawa1, Yuta Takamura1, Tomoyuki Miyao1, Ryutaro Yamazaki2, Satoko Arai1, Takayoshi Owada1, Reika Maezawa1 and Masafumi Arima1, 1Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, 2Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan

    Background/Purpose: We previously reported that there was patterns of coexistence of pulmonary lesions and airway disease (AD) were common abnormities of patients with pulmonary involvement.…
  • Abstract Number: 523 • 2018 ACR/ARHP Annual Meeting

    The Prevalence and Clinical Characteristics of Rheumatoid Arthritis with Interstitial Lung Disease in the San Joaquin Valley of Central California

    Candice Yuvienco1, Matthew White2, Kyle Heber3 and Ratnali Jain2, 1Internal Medicine, Division of Rheumatology, University of California San Francisco, Fresno Medical Education Program, Fresno, CA, 2Internal Medicine, University of California San Francisco - Fresno Medical Education Program, Fresno, CA, 3IM, UCSF Fresno, Fresno, CA

    Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease of systemic inflammation primarily involving the small synovial joints. Approximately 1.5 million adults in the United States…
  • Abstract Number: 524 • 2018 ACR/ARHP Annual Meeting

    Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice

    Cristina Vadillo Font1, María A Nieto2, Dalifer Freites Núñez3, Zulema Rosales Rosado1,3, Leticia Leon3, Judit Font Urgelles1, Juan A Jover Jover1 and Lydia A Alcazar3, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Chest diseases, Hospital Clínico San Carlos, Madrid, Spain, 3Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: Interstitial lung disease (ILD) is the extra-articular manifestation that most frequently worsens the course of Rheumatoid arthritis (RA) disease. Purpose: To describe the characteristics…
  • Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting

    Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program

    Gustavo Citera1, Eduardo Mysler2, Hugo Madariaga3, Mario H Cardiel4, Oswaldo Castañeda5, Aryeh Fischer6, Pascal Richette7, Sandra Chartrand8, Jin Kyun Park9, Sander Strengholt10, Jose L Rivas11, Amit Thorat12, Tanya Girard13, Kenneth Kwok14, Lisy Wang15 and Dario Ponce de Leon16, 1Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Organización Médica de Investigación, Buenos Aires, Argentina, 3Clínica del Sur, Arequipa, Peru, 4Centro de Investigación Clínica de Morelia, Morelia, Mexico, 5Clínica Anglo Americana, Lima, Peru, 6Department of Medicine, University of Colorado, Denver, CO, 7Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, 8Department of Medicine, Hôpital Maisonneuve-Rosemont affiliated to Université de Montréal, Montréal, QC, Canada, 9Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), 10Pfizer Inc, Capelle aan den IJssel, Netherlands, 11Pfizer SLU, Madrid, Spain, 12Pfizer Ltd, Mumbai, India, 13Pfizer Inc, Montréal, QC, Canada, 14Pfizer Inc, New York, NY, 15Pfizer Inc, Groton, CT, 16Pfizer Inc, Lima, Peru

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…
  • Abstract Number: 526 • 2018 ACR/ARHP Annual Meeting

    Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease

    Kyoko Honne1, Masashi Bando2, Makiko Mieno3, Masahiro Iwamoto4 and Seiji Minota5, 1Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 2division of pulmonary medicine, Department of medicine, Jichi Medical University, Shimotsuke, Japan, 3Center for Information, Jichi Medical University, Shimotsuke, Japan, 4Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 5Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: Interstitial lung disease (ILD) is a risk factor of pneumonia in RA patients treated with biological DMARDs (bDMARDs) [1-4]. Bronchiectasis (BE) is a well-known…
  • Abstract Number: 527 • 2018 ACR/ARHP Annual Meeting

    Long-Term Follow up of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis

    Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: Using of high-resolution computed tomography(HRCT) has increased the early detection of interstitial lung disease(ILD) in asymptomatic and undiagnosed individuals. This study was to identify…
  • Abstract Number: 528 • 2018 ACR/ARHP Annual Meeting

    Progression in Interstitial Lung Disease – Comparison of Rheumatoid Arthritis with Idiopathic Pulmonary Fibrosis

    Shirish Dubey1 and Felix Woodhead2, 1Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, 2Respiratory Medicine, Glenfields Hospital, Leicester, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) is a common autoimmune condition characterised by symmetrical inflammatory small joint polyarthropathy and loss of function. Systemic manifestations of RA are…
  • Abstract Number: 529 • 2018 ACR/ARHP Annual Meeting

    Chest Computed Tomography Abnormalities in Patients with Rheumatoid Arthritis By Serologic Status

    Sicong Huang1, Tracy Doyle2, Allison Marshall3, Christine K Iannaccone4, Jie Huang1, Michael E Weinblatt2, Paul F. Dellaripa5, Elizabeth Karlson5, Nancy A. Shadick2 and Jeffrey A. Sparks1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Lung involvement in rheumatoid arthritis (RA) has been recognized as an important contributor to morbidity and mortality. While interstitial lung disease (ILD) is a…
  • Abstract Number: 530 • 2018 ACR/ARHP Annual Meeting

    RA-Voice: Evaluating Laryngeal Involvement in Rheumatoid Arthritis Patients

    Ana Águeda1, Luisa Azevedo2, Joaquim Vieira2, Sandra Augusto2, Catarina Ambrósio1, Inês Cunha1 and Anabela Barcelos1, 1Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, 2Otolaryngology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal

    Background/Purpose: Laryngeal involvement is not uncommon in connective tissue diseases including Rheumatoid Arthritis (RA). Its prevalence has been estimated between 5% and 70% of patients…
  • « Previous Page
  • 1
  • …
  • 1037
  • 1038
  • 1039
  • 1040
  • 1041
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology